William Goolsbee
Director/Board Member chez HELIX BIOMEDIX, INC.
Profil
William Alden Goolsbee was the founder of Horizon Medical, Inc. (founded in 1987) where he held the title of Chairman & Chief Executive Officer in 2002.
He is currently the Chairman & Chief Executive Officer at BMG Hematology LLC and an Independent Director at Helix BioMedix, Inc. He previously served as Chairman of Immunotherapy Corp.
from 1995 to 1998, Chairman of BMG Pharma LLC from 2006 to 2011, Chairman of Metrodora Therapeutics, Inc., Independent Director at Sarepta Therapeutics, Inc. from 2014 to 2016, and Independent Non-Executive Director at Percheron Therapeutics Ltd.
from 2015 to 2021.
Mr. Goolsbee obtained his undergraduate degree from the University of California, Santa Barbara.
Postes actifs de William Goolsbee
Sociétés | Poste | Début |
---|---|---|
HELIX BIOMEDIX, INC. | Director/Board Member | 01/01/2019 |
BMG Hematology LLC | Chief Executive Officer | - |
Anciens postes connus de William Goolsbee
Sociétés | Poste | Fin |
---|---|---|
PERCHERON THERAPEUTICS LIMITED | Director/Board Member | 15/12/2021 |
SAREPTA THERAPEUTICS, INC. | Chairman | 30/07/2014 |
Metrodora Therapeutics, Inc. | Chairman | 01/01/2015 |
BMG Pharma LLC | Chairman | 01/01/2011 |
Horizon Medical, Inc. | Chief Executive Officer | 01/01/2002 |
Formation de William Goolsbee
University of California, Santa Barbara | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 3 |
---|---|
HELIX BIOMEDIX, INC. | Health Technology |
SAREPTA THERAPEUTICS, INC. | Health Technology |
PERCHERON THERAPEUTICS LIMITED | Health Technology |
Entreprise privées | 5 |
---|---|
Horizon Medical, Inc. | Health Technology |
Immunotherapy Corp.
Immunotherapy Corp. Pharmaceuticals: OtherHealth Technology Part of Sarepta Therapeutics, Inc., Immunotherapy Corp. develops cancer treatments. The private company is based in Seattle, WA. The CEO of the company is Amnon Gonenne. Immunotherapy was acquired by AntiVirals, Inc. on November 06, 1997 for $24 million. | Health Technology |
BMG Pharma LLC | |
BMG Hematology LLC | |
Metrodora Therapeutics, Inc. |